UBS Asset Management Americas Inc. acquired a new stake in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 589,490 shares of the biopharmaceutical company’s stock, valued at approximately $5,423,000. UBS Asset Management Americas Inc. owned about 1.06% of CymaBay Therapeutics at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. raised its stake in CymaBay Therapeutics by 12.6% during the fourth quarter. BlackRock Inc. now owns 690,679 shares of the biopharmaceutical company’s stock valued at $6,354,000 after buying an additional 77,459 shares during the last quarter. Wells Fargo & Company MN raised its stake in CymaBay Therapeutics by 7,729.2% during the fourth quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 38,646 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new position in CymaBay Therapeutics during the fourth quarter valued at $1,242,000. Sigma Planning Corp raised its stake in CymaBay Therapeutics by 82.0% during the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 12,300 shares during the last quarter. Finally, California Public Employees Retirement System purchased a new position in CymaBay Therapeutics during the fourth quarter valued at $487,000. Institutional investors and hedge funds own 61.36% of the company’s stock.
CymaBay Therapeutics Inc (NASDAQ:CBAY) opened at $15.00 on Monday. CymaBay Therapeutics Inc has a one year low of $3.16 and a one year high of $15.59. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $831.15, a price-to-earnings ratio of -14.70 and a beta of 1.96.
A number of research analysts have issued reports on CBAY shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Leerink Swann restated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Roth Capital restated a “buy” rating and issued a $27.00 price target on shares of CymaBay Therapeutics in a research note on Thursday, January 25th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. CymaBay Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.89.
ILLEGAL ACTIVITY NOTICE: “UBS Asset Management Americas Inc. Acquires Shares of 589,490 CymaBay Therapeutics Inc (CBAY)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/12/ubs-asset-management-americas-inc-acquires-shares-of-589490-cymabay-therapeutics-inc-cbay.html.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.